Fibrosis pulmonar idiopática (FPI)

 

Disease progression events in trials of nintedanib in patients with idiopathic pulmonary fibrosis

Nathan SD et al.
 

Acceder

Effect of nintedanib in subgroups based on combined pulmonary fibrosis and emphysema (CPFE) index at baseline

Cottin V et al.
 

Acceder

Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and multiple comorbidities

Glaspole I et al.
 

Acceder

 

 

Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis: subgroup analyses by TORVAN stage

Torrisi SE et al.
 

Acceder

Gene expression profiling in patients with idiopathic pulmonary fibrosis (IPF) in the INMARK trial

Selman M et al.

 

Acceder

Gene expression profiling in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil: data from the INSTAGE trial

Bonella F et al.
 

Acceder

 

 

Association of circulating proteins with death or lung transplant in the IPF-PRO Registry cohort

Todd JL et al.

 

Acceder

Relationship between mRNA-microRNA interactions and forced vital capacity in patients with idiopathic pulmonary fibrosis

Noth I et al.
 

Acceder

Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry

Snyder LD et al.

 

Acceder

 

 

In-hospital mortality in patients with idiopathic pulmonary fibrosis

Judy J et al.

 

Acceder

Impact of pre-transplant anti-fibrotic therapy for IPF upon lung transplant outcomes

Astor T et al.
 

Acceder